Melanoma drug duel: which combo boosts immunity more?
NCT ID NCT07223411
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how two different drug combinations affect the immune system in people with advanced melanoma that cannot be removed by surgery. Researchers will compare Opdualag (nivolumab/relatlimab) with cemiplimab/fianlimab by analyzing blood and tumor samples from 20 participants. The goal is to understand which treatment triggers a stronger immune response, potentially helping doctors choose the best therapy in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Opdualag (nivolumab/relatlimab) and cemiplimab/fianlimab
What this could lead to
If successful, this study could reveal which drug combination triggers a stronger immune response against melanoma, guiding future treatment choices.
What could go wrong
This is a small, early-stage translational study with only 20 participants, so results may not apply broadly. It focuses on immune markers, not direct patient outcomes like survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact